Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Jan 02, 2013 8:46am
285 Views
Post# 20787839

RE: What is up With BRD? - Management Risk

RE: What is up With BRD? - Management Risk

 

Josa:

 

Lets not forget that the recent "fiscal cliff" and world financial turmoil played havoc with the "risk-on" "risk-off" trade aspect of market appreciation of junior miners. Historically, in a gold market cycle, the T1's with be the beneficiary of new money, with profits being redeployed into the T2's then the producing T3's (unhedged) and then finally the T3's with a hedge (or streaming agreement), etc. With varying combinations of T3's.

 

Nolan Watson's interview in the PWC link posted is adamant that management risk is one of the key parameters in his bucket list. Point being, I've seen first hand the (reactive versus proactive) management style of managers coming from the milling or other sides of an operation. In an ideal world, a professionally designated manager with face to boardroom experience is the ideal; while not always possible. Plus there is a HUGE difference between and exploration, pre-production and steady state operation. Hence the recent misfire(s).

 

The recent announcement of DR (not salesman Dave Russell) could be an attempt to mitigate/address the management risk of BRD as per Nolan Watson's concern for ALL managers if the streaming companies that he brings into his portfolio.

 

See the comments/exchange at the end of the link posted below (borrowed from the Sandstorm Board):

 

https://www.investmentrevaluationcatalyst.com/2012/12/brigus-grey-fox.html

 

BWDIK? The gold market cycle (T1, T2, T3) has been a historical market phenomenon. BRD has been addressing/de-risking some of the areas where investors MAY have cause for concern in order to move from T3 to a T2 (mid-tier). Sometimes opportunities (like using an adjacent property for access to GF UG) can save MILLIONS in development costs, provided that the overburden, strike and dips are favourable.

 

Cheers

Stanley

 

Bullboard Posts